South Korea · Delayed Price · Currency is KRW LabGenomics Statistics
Total Valuation
LabGenomics has a market cap or net worth of KRW 56.13 billion. The enterprise value is 63.72 billion.
| Market Cap | 56.13B |
| Enterprise Value | 63.72B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LabGenomics has 74.24 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 74.24M |
| Shares Outstanding | 74.24M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 5.57% |
| Float | 59.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.67 |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.17 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.07 |
| Interest Coverage | -9.02 |
Financial Efficiency
Return on equity (ROE) is -35.39% and return on invested capital (ROIC) is -35.14%.
| Return on Equity (ROE) | -35.39% |
| Return on Assets (ROA) | -12.74% |
| Return on Invested Capital (ROIC) | -35.14% |
| Return on Capital Employed (ROCE) | -30.68% |
| Weighted Average Cost of Capital (WACC) | 5.74% |
| Revenue Per Employee | 801.81M |
| Profits Per Employee | -606.74M |
| Employee Count | 105 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 18.45 |
Taxes
In the past 12 months, LabGenomics has paid 4.81 billion in taxes.
| Income Tax | 4.81B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.24% in the last 52 weeks. The beta is -0.10, so LabGenomics's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -68.24% |
| 50-Day Moving Average | 1,182.24 |
| 200-Day Moving Average | 1,724.16 |
| Relative Strength Index (RSI) | 33.70 |
| Average Volume (20 Days) | 2,963,293 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LabGenomics had revenue of KRW 84.19 billion and -63.71 billion in losses. Loss per share was -859.34.
| Revenue | 84.19B |
| Gross Profit | 27.76B |
| Operating Income | -53.38B |
| Pretax Income | -58.90B |
| Net Income | -63.71B |
| EBITDA | -44.06B |
| EBIT | -53.38B |
| Loss Per Share | -859.34 |
Balance Sheet
The company has 53.87 billion in cash and 61.47 billion in debt, with a net cash position of -7.60 billion or -102.31 per share.
| Cash & Cash Equivalents | 53.87B |
| Total Debt | 61.47B |
| Net Cash | -7.60B |
| Net Cash Per Share | -102.31 |
| Equity (Book Value) | 149.16B |
| Book Value Per Share | 2,009.10 |
| Working Capital | 10.43B |
Cash Flow
In the last 12 months, operating cash flow was -28.49 billion and capital expenditures -1.26 billion, giving a free cash flow of -29.75 billion.
| Operating Cash Flow | -28.49B |
| Capital Expenditures | -1.26B |
| Depreciation & Amortization | 9.32B |
| Net Borrowing | 2.20B |
| Free Cash Flow | -29.75B |
| FCF Per Share | -400.74 |
Margins
Gross margin is 32.98%, with operating and profit margins of -63.40% and -75.67%.
| Gross Margin | 32.98% |
| Operating Margin | -63.40% |
| Pretax Margin | -69.96% |
| Profit Margin | -75.67% |
| EBITDA Margin | -52.33% |
| EBIT Margin | -63.40% |
| FCF Margin | n/a |
Dividends & Yields
LabGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | -113.51% |
| FCF Yield | -53.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
LabGenomics has an Altman Z-Score of 1.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.23 |
| Piotroski F-Score | 2 |